Hospira, Stada Collaboration To Yield Biosimilar EPO In The EU Ahead Of U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Hospira obtains exclusive distribution rights for Bioceuticals erythropoietin in the EU and will be solely responsible for U.S. development.
You may also be interested in...
Stada Enjoys Robust First Half For Generics And Biosimilars
With generics and biosimilars sales continuing to flow in the first half of 2022, Stada reported healthy top- and bottom-line growth for the first six months of the year, including a 23% rise for its adjusted EBITDA.
Next Round Of Epoetin Alfa Biosimilars To Reach Europe In 2008
European Commission approves marketing for Epo-zeta products Hospira's Retacrit, Stada Arzneimittel's Silapo on basis of similarity to J&J's Procrit.
Next Round Of Epoetin Alfa Biosimilars To Reach Europe In 2008
European Commission approves marketing for Epo-zeta products Hospira's Retacrit, Stada Arzneimittel's Silapo on basis of similarity to J&J's Procrit.